Mustang Bio MBIO reported updated results from a cohort of an ongoing phase I/II study evaluating its lead clinical candidate MB-106 in patients with Waldenstrom macroglobulinemia (WM), a rare form of...
Source LinkMustang Bio MBIO reported updated results from a cohort of an ongoing phase I/II study evaluating its lead clinical candidate MB-106 in patients with Waldenstrom macroglobulinemia (WM), a rare form of...
Source Link
Comments